PET/CT scan to guide liver transplant decisions in liver cancer
Part of Cancer, Digestive system clinical trials.
This trial studies how a whole-body PET/CT scan using a “tracer” called 18F-FDG can help decide which people with liver cancer (HCC) may benefit from a liver transplant. It may help the transplant team better sort out who is likely to do well after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer (hepatocellular carcinoma, or HCC).
- You are being evaluated for a liver transplant after a team discussion (multidisciplinary review).
- You are between 18 and 80 years old (inclusive).
- You do not have serious health problems that would make transplant unsafe due to reasons unrelated to the liver cancer (for example, uncontrolled infection, significant heart or lung disease, inability to follow the plan, active alcohol abuse, or certain mental health/psychiatric issues).
- Your liver cancer should not have spread outside the liver in ways that rule out transplant, such as distant metastases, lymph node involvement, or major blood-vessel invasion.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well special imaging scans (PET/CT or PET/MRI) work in adults with suspected or diagnosed liver cancer. It may help doctors better see the cancer and plan next steps.
This trial tests a special PET scan (18F-FSPG) to help guide therapy for people with liver cancer (HCC) who are planning to receive Y90 radioembolization. The scan may help doctors better plan your treatment.
This study compares different scan types (MRI, CT, and two PET scans) in people with hepatocellular carcinoma (a primary liver cancer). It may help doctors figure out which scan gives the most useful information for diagnosis and treatment planning.
This trial is testing a new way to see how well patients do after a liver transplant. It includes people with severe cirrhosis, other end-stage liver diseases, or liver cancer.
This study tests a new imaging tracer to better see liver cancer on PET scans, which might help doctors find or monitor tumors more accurately.
This trial tests a new imaging technique that may help doctors see liver cancer more clearly. It uses a special tracer that targets a protein found on many liver cancer cells. This could help with diagnosis and monitoring.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.